SciVision Biotech Inc - Asset Resilience Ratio
SciVision Biotech Inc (1786) has an Asset Resilience Ratio of 7.46% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 1786 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how SciVision Biotech Inc's Asset Resilience Ratio has changed over time. See SciVision Biotech Inc (1786) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down SciVision Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SciVision Biotech Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$194.63 Million | 7.46% |
| Total Liquid Assets | NT$194.63 Million | 7.46% |
Asset Resilience Insights
- Limited Liquidity: SciVision Biotech Inc maintains only 7.46% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
SciVision Biotech Inc Industry Peers by Asset Resilience Ratio
Compare SciVision Biotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
iRay Technology Co Ltd
SHG:688301 |
Medical Instruments & Supplies | 0.68% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 51.82% |
|
Jiangsu Nanfang Medical
SHG:603880 |
Medical Instruments & Supplies | 2.27% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 4.42% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 6.36% |
|
Austco Healthcare Ltd
AU:AHC |
Medical Instruments & Supplies | 15.90% |
|
Trajan Group Holdings Ltd
AU:TRJ |
Medical Instruments & Supplies | 0.23% |
|
Osteopore Ltd
AU:OSX |
Medical Instruments & Supplies | 43.09% |
Annual Asset Resilience Ratio for SciVision Biotech Inc (2011–2024)
The table below shows the annual Asset Resilience Ratio data for SciVision Biotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 7.03% | NT$165.40 Million ≈ $5.21 Million |
NT$2.35 Billion ≈ $74.18 Million |
-6.54pp |
| 2023-12-31 | 13.56% | NT$292.95 Million ≈ $9.23 Million |
NT$2.16 Billion ≈ $68.06 Million |
+9.42pp |
| 2022-12-31 | 4.14% | NT$86.87 Million ≈ $2.74 Million |
NT$2.10 Billion ≈ $66.11 Million |
+2.51pp |
| 2021-12-31 | 1.63% | NT$36.92 Million ≈ $1.16 Million |
NT$2.26 Billion ≈ $71.26 Million |
+0.79pp |
| 2020-12-31 | 0.84% | NT$15.94 Million ≈ $502.29K |
NT$1.89 Billion ≈ $59.57 Million |
-4.38pp |
| 2019-12-31 | 5.23% | NT$97.29 Million ≈ $3.07 Million |
NT$1.86 Billion ≈ $58.66 Million |
+4.27pp |
| 2018-12-31 | 0.96% | NT$16.21 Million ≈ $510.70K |
NT$1.70 Billion ≈ $53.43 Million |
-0.09pp |
| 2017-12-31 | 1.05% | NT$16.37 Million ≈ $515.84K |
NT$1.56 Billion ≈ $49.25 Million |
-9.27pp |
| 2016-12-31 | 10.32% | NT$140.02 Million ≈ $4.41 Million |
NT$1.36 Billion ≈ $42.76 Million |
-11.64pp |
| 2015-12-31 | 21.96% | NT$235.55 Million ≈ $7.42 Million |
NT$1.07 Billion ≈ $33.80 Million |
-9.14pp |
| 2014-12-31 | 31.10% | NT$339.61 Million ≈ $10.70 Million |
NT$1.09 Billion ≈ $34.40 Million |
+13.56pp |
| 2013-12-31 | 17.54% | NT$198.03 Million ≈ $6.24 Million |
NT$1.13 Billion ≈ $35.57 Million |
-10.72pp |
| 2012-12-31 | 28.26% | NT$136.59 Million ≈ $4.30 Million |
NT$483.28 Million ≈ $15.23 Million |
-5.31pp |
| 2011-12-31 | 33.58% | NT$135.61 Million ≈ $4.27 Million |
NT$403.87 Million ≈ $12.72 Million |
-- |
About SciVision Biotech Inc
SciVision Biotech Inc. develops and manufactures medical-grade hyaluronic acid products in Taiwan. The company offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. It also involved in international trade; wholesale of medical equipment and cosmetics; and provides management advisory services. SciVision Biotech Inc. was fo… Read more